Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.,The Lancet - X-MOL
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study | Leukemia
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR | Haematologica
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study | Blood Cancer Journal
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA | Leukemia
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma | NEJM
Frontiers | Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Additional Trials | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, E | CMAR
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX | Blood Cancer Journal
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial - The Lancet Oncology
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR - ScienceDirect
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk | Journal of Hematology & Oncology | Full Text
Phase III Intervention Study for Multiple Myeloma
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study | Leukemia
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma | NEJM
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
The Lancet Twitterissä: "Presenting now at #ASH19 @ASH_hematology—Overall survival with daratumumab, bortezomib, melphalan and prednisone in newly diagnosed #multiplemyeloma (ALCYONE): a randomised, open-label, phase 3 trial Free to read (with free reg)
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies | Haematologica
Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma - The ASCO Post
Ash 2018 – Survival benefit or no, Darzalex has a new use | Evaluate
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma | NEJM
Overall survival after discontinuation of daratumumab. (A) Overall... | Download Scientific Diagram
JCM | Free Full-Text | Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
MAIA Study | Int'l Myeloma Foundation
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials - The Lancet Haematology
Limited efficacy of daratumumab and selected differentially expressed... | Download Scientific Diagram
